1. Maudsley H. The Pathology of Mind (3rd edn). London: Macmillan; 1979.

2. Medunad LJ, Gerty FJ, Urse VG. Biochemical disturbances in mental disorders. Arch

Neurol Psychiatry 1942;47:38-52.

3. Ameson GA. Phenothizine derivatives and glucose metabolism. J Neuropsychiatry

1964;5:181-185.

4. Hiles BW. Hyperglycemia and glycosuria following chlorpromazine therapy. JAMA

1956;162:1651.

5. Thonnard-Neumann E. Phenothiazines and diabetes in hospitalized women. Am J

Psychiatry 1968;124:978-982.

6. Kamran A, Doraiswamy PM, Jane JL. Severe hyperglycemia associated with high doses of

clozapine (letter). Am J Psychiatry 1994;151:1395.

7. Wirshing DA, Spelberg BJ, Erhart SM. Novel antipsychotics and new onset diabetes. Biol

Psychiaty 1998;44:778-783.

8. Wirshing DA, Wirshing WC, Kysar L. Novel antipsychotics: Comparison of weight gain

liabilities. J Clin Psychiatry 1999;60:358-363.

9. Henderson DC. Schizophrenia and Comorbid Metabolic Disorders. J Clin Psychiatry,

2005;66:11–20.

10. Newcomer JW, Haupt DW, Fucetola R, et al. Abnormalities in glucose regulation during

antipsychotic treatment of schizophrenia. Arch Gen Psychiatry 2002;59:337-345.

11. Psychopharmacol (Berl) Wu RR, Zhao JP, Liu ZN, et al. Effects of typical and atypical

antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode

schizophrenia. 2006;186:572-578.
12. World Health Organization. The ICD-10 classification of mental and behavioural

disorders: diagnostic criteria for research. World Health Organization, Geneva; 1992.

13. Matthews DR, Hosker JP, Rudenski AS, et al. (1985). Homeostasis model assessment:

insulin resistance and beta-cell function from fasting plasma glucose and insulin

concentrations in man. Diabetologia 1985;28:412–419.

14. Hermans MP, Levy JC, Morris RJ, et al. Comparison of tests of ß-cell function across a

range of glucose tolerance from normal to diabetes. Diabetes 1999;48:1779–1786.

15. Wallace TM, Levy JC, Matthews DR. Use and abuse of homa modeling. Diabetes Care

2004;27:1487-1495.

16. Reinehr T, Andler W. Changes in the atherogenic risk factor profile according to degree

of weight loss. Arch Dis Child 2004;89:419–422.

17. Katsuki A, Sumida Y, Gabazza EC, et al. Homeostasis Model Assessment is a reliable

indicator of insulin resistance during follow-up of patients with type 2 diabetes. Diabetes

Care 2001;24:362–365.

18. Wu RR, Zhao JP, Zhai JG, et al. Sex difference in effects of typical and atypical

antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode

schizophrenia. J Clin Psychopharmacol 2007;27:374-9.

19. Defronzo RA. Pathogenesis of type 2 doabetes: metabolic and molecular implications for

identifying diabetes genes. Diabetes Metab Rev 1997;5:177-269.

20. Selke G, Fucetola R, Cooper BP. Atypical antipsychotic-induced differences in glucose

regulation in schizophrenia independent of differences in adiposity. Soc Neurosci Abstr

2000;26:275.
21. Dwyer DS, Liu Y, Bradley RJ. Dopamine receptor antagonists modulate glucose uptake in

rat pheochromocytoma (PC12) cells. Neurosci Lett 1999;274:151-154.

22. Erle G, Basso M, Federspil G. Effect of chlorpromazine on blood glucose and plasma

insulin in man. Eur J Clin Pharmacol 1977;11:15-18.

23. Sato S, Katayama K, Kakemi M. A kinetic study of schlorpromazine on the hyperglycemic

response in rats, 2: effect of chlorpromazine on plasma glucose. J Pharmacobiodyn

1988;11:492-503.